No Effect of the 1α,25-Dihydroxyvitamin D3 on β-Cell Residual Function and Insulin Requirement in Adults With New-Onset Type 1 Diabetes
M Walter, T Kaupper, K Adler, J Foersch… - Diabetes …, 2010 - Am Diabetes Assoc
M Walter, T Kaupper, K Adler, J Foersch, E Bonifacio, AG Ziegler
Diabetes care, 2010•Am Diabetes AssocOBJECTIVE To determine whether daily intake of 1α, 25-dihydroxyvitamin D3 [1, 25 (OH)
2D3] is safe and improves β-cell function in patients with recently diagnosed type 1 diabetes.
RESEARCH DESIGN AND METHODS Safety was assessed in an open study of 25 patients
aged 18–39 years with recent-onset type 1 diabetes who received 0.25 μg 1, 25 (OH) 2D3
daily for 9 months. An additional 40 patients were randomly assigned to 0.25 μg 1, 25 (OH)
2D3 or placebo daily for 9 months and followed for a total of 18 months for safety, β-cell …
2D3] is safe and improves β-cell function in patients with recently diagnosed type 1 diabetes.
RESEARCH DESIGN AND METHODS Safety was assessed in an open study of 25 patients
aged 18–39 years with recent-onset type 1 diabetes who received 0.25 μg 1, 25 (OH) 2D3
daily for 9 months. An additional 40 patients were randomly assigned to 0.25 μg 1, 25 (OH)
2D3 or placebo daily for 9 months and followed for a total of 18 months for safety, β-cell …
OBJECTIVE
To determine whether daily intake of 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3] is safe and improves β-cell function in patients with recently diagnosed type 1 diabetes.
RESEARCH DESIGN AND METHODS
Safety was assessed in an open study of 25 patients aged 18–39 years with recent-onset type 1 diabetes who received 0.25 μg 1,25(OH)2D3 daily for 9 months. An additional 40 patients were randomly assigned to 0.25 μg 1,25(OH)2D3 or placebo daily for 9 months and followed for a total of 18 months for safety, β-cell function, insulin requirement, and glycemic control.
RESULTS
Safety assessment showed values in the normal range in nearly all patients, regardless of whether they received 1,25(OH)2D3 or placebo. No differences in AUC C-peptide, peak C-peptide, and fasting C-peptide after a mixed-meal tolerance test between the treatment and placebo groups were observed at 9 and 18 months after study entry, with ∼40% loss for each parameter over the 18-month period. A1C and daily insulin requirement were similar between treatment and placebo groups throughout the study follow-up period.
CONCLUSIONS
Treatment with 1,25(OH)2D3 at a daily dose of 0.25 μg was safe but did not reduce loss of β-cell function.
Am Diabetes Assoc